| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to …
Over the last 12 months, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $0 worth of Foghorn Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $1.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $2.4M was made by Flagship Ventures Fund V General Partner LLC (10 percent owner) on 2020‑10‑27.
| 2024-09-23 | Sale | Costa Carlos | Chief People Officer | 857 0.0017% | $10.17 | $8,716 | -47.00% | |
| 2024-09-20 | Sale | Costa Carlos | Chief People Officer | 35,756 0.0649% | $10.04 | $358,990 | -50.65% | |
| 2024-09-18 | Sale | Costa Carlos | Chief People Officer | 11,574 0.022% | $10.05 | $116,319 | -48.33% | |
| 2024-09-17 | Sale | Costa Carlos | Chief People Officer | 10,272 0.0189% | $10.04 | $103,131 | -49.80% | |
| 2024-09-16 | Sale | Costa Carlos | Chief People Officer | 400 0.0008% | $10.00 | $4,000 | -46.38% | |
| 2024-09-09 | Sale | Bellon Steven F. | Chief Scientific Officer | 20,000 0.0366% | $9.50 | $190,000 | -46.85% | |
| 2024-03-11 | Sale | Cavalie Fanny | Chief Strategy/Bus Ops Officer | 11,000 0.0249% | $6.56 | $72,134 | -11.01% | |
| 2023-08-16 | Sale | Agresta Samuel | Chief Medical Officer | 311,297 0.6823% | $8.25 | $2.57M | -35.56% | |
| 2020-10-27 | Flagship Ventures Fund V General Partner LLC | 10 percent owner | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | ||
| 2020-10-27 | Abu Dhabi Investment Authority | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | |||
| 2020-10-27 | DECICCO CARL | Chief Scientific Officer | 5,500 0.0498% | $16.00 | $88,000 | -20.50% |
| Flagship Ventures Fund V General Partner LLC | 10 percent owner | 9330878 15.7124% | $19.87M | 1 | 0 | <0.0001% |
| Abu Dhabi Investment Authority | 1231081 2.073% | $2.62M | 1 | 0 | <0.0001% | |
| DECICCO CARL | Chief Scientific Officer | 258397 0.4351% | $550,385.61 | 1 | 0 | <0.0001% |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 46 | +52.87% | 2M | +5.71% |
| Decreased Positions | 32 | -36.78% | 828,345 | -2.05% |
| New Positions | 15 | New | 817,618 | New |
| Sold Out Positions | 9 | Sold Out | 223,298 | Sold Out |
| Total Postitions | 101 | +16.09% | 42M | +3.66% |
| Flagship Pioneering Inc. | $65,779.00 | 22.24% | 12.67M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $28,413.00 | 9.6% | 5.47M | -60,025 | -1.08% | 2025-09-30 |
| Bvf Inc/Il | $27,517.00 | 9.3% | 5.3M | 0 | 0% | 2025-09-30 |
| Deerfield Management Company, L.P. | $16,896.00 | 5.71% | 3.26M | 0 | 0% | 2025-09-30 |
| Raymond James Financial Inc | $12,780.00 | 4.32% | 2.46M | +95,196 | +4.02% | 2025-09-30 |
| Blackrock, Inc. | $11,729.00 | 3.97% | 2.26M | +30,815 | +1.38% | 2025-09-30 |
| Vanguard Group Inc | $9,858.00 | 3.33% | 1.9M | +14,784 | +0.78% | 2025-09-30 |
| Euclidean Capital Llc | $8,168.00 | 2.76% | 1.57M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $4,196.00 | 1.42% | 808,488 | +814 | +0.1% | 2025-09-30 |
| Siren, L.L.C. | $3,741.00 | 1.26% | 720,720 | 0 | 0% | 2025-09-30 |